Glutamic acid decarboxylase antibodies are more frequent than islet cell antibodies in islet transplanted IDDM patients and persist or occur despite immunosuppression

Journal of Molecular Medicine

Volumn 77, Issue 1, 1999, Pages 45-48

  Jaeger, C ^a   Hering, B J ^a   Hatziagelaki, E ^a   Federlin, K ^a   Bretzel, R G ^a  

^a Third Med Department and Policlinic   (Germany)

Author keywords

Autoimmunity; Disease recurrence; GAD 65 antibodies; Islet cell antibodies; Islet transplantation

Indexed keywords

GLUTAMATE DECARBOXYLASE; PANCREAS ISLET CELL ANTIBODY;

ADULT; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; GRAFT FAILURE; GRAFT REJECTION; HUMAN; IMMUNOASSAY; IMMUNOFLUORESCENCE; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; KIDNEY TRANSPLANTATION; PANCREAS ISLET TRANSPLANTATION; RECURRENT DISEASE;

EID: 0033043975     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001090050299     Document Type: Conference Paper

References (20)

1. 1. Naji A, Silvers WK, Bellgrau D, Barker CF (1981) Spontaneous diabetes in rats: destruction of islets is prevented by immunologic tolerance. Science 213: 1390-1391
2. 2. Wöhrle M, Pullmann J, Bretzel RG, Federlin K (1992) Prevention of recurrent autoimmune diabetes in the BB rat by islet transplantation under the renal capsule. Transplantation: 1099-1102
3. 3. Bartlett ST, Hadley GA, Dirden B, Schweitzer EJ, Eans S, Pham D, Sheffield C (1993) Composite kidney-islet transplantation prevents recurrent autoimmune beta-cell destruction. Surgery 114: 211-217
4. 4. Bartlett ST, Chin T, Dirden B, Quereshi A, Hadley G (1995) Inclusion of peripancreatic lymph node cells prevents recurrent autoimmune destruction of islet transplants: evidence of donor chimerism. Surgery 118: 392-397
5. 5. Sibley RK, Sutherland DER, Goetz F, Michael AF (1985) Recurrent diabetes mellitus in the pancreas iso- and allograft; a light and electron microscopic and immunohistochemical analysis of four cases. Lab Invest 53: 132-144
6. 6. Tyden G, Reinholt FP, Sundkvist G, Bolinder J (1996) Recurrence of autoimmune diabetes mellitus in recipients of cadaveric pancreatic grafts. N Engl J Med 335: 860-863
7. 7. Stegall MD, Lafferty KJ, Kam I, Gill RG (1996) Evidence of recurrent autoimmunity in human allogenic islet transplantation. Transplantation 63: 1272-1274
8. 8. Jaeger C, Hering BJ, Dyrberg T, Federlin K, Bretzel RG (1996) Islet cell antibodies and glutamic acid decarboxylase antibodies in patients with insulin-dependent diabetes mellitus undergoing kidney and islet-after-kidney transplantation. Transplantation 62: 424-426
9. 9. Atkinson MA, MacLaren NK (1994) The pathogenesis of insulin-dependent diabetes mellitus. N Engl J Med 331: 1428-1436
10. 10. Bretzel RG, Browatzki CC, Schultz A, Brandhorst H, Klitscher D, Bollen CC, Raptis G, Friemann S, Ernst W, Rau WS, Hering BJ (1993) Clinical islet transplantation - report of the islet transplant registry and the Giessen center experience. Diab Stoffw 2: 378-390
11. 11. Peterson JC, Hejnaes KR, Moody A, Karlsen AE, Marshall MO, Hoier-Madsen M, Boel E, Michelsen B, Dyrberg T (1994) Detection of GAD 65 antibodies in diabetes and other autoimmune diseases using a simple radioligand assay. Diabetes 43: 459-467
12. 12. Bougneres PF, Landais P, Boisson C et al (1990) Limited duration of remission of insulin dependency in children with recent overt typeI diabetes treated with low-dose cyclosporine. Diabetes 39: 1264-1472
13. 13. Rakotoambinina B, Timsit J, Deschamps I et al (1995) Cyclosporine A does not delay insulin dependency in asymptomatic IDDM patients. Diabetes Care 18: 1487-1490
14. 14. Eisenbarth GS, Stegall M (1996) Islet and pancreatic transplantation - autoimmunity and alloimmunity. N Engl J Med 335: 888-889
15. 15. Peterson JS, Dyrberg T, Karlsen AE, Molvig J, Michelsen B, Nerup J, Mandrup-Poulsen T, and the Canadian-European Randomized Control Trial Goup (1994) Glutamic acid decarboxylase (GAD 65) autoantibodies in prediction of b-cell function and remission in recent-onset IDDM after cyclosporin treatment. Diabetes 43: 1291-1296
16. 16. Mandrup-Poulson T, Nerup J, Stiller CR, Marner B, Bille G, Heinrichs D, Martell R, Dupre J, Keown PA, Jenner MR, Rodger NW, Wolfe B, Graffenried BV, Binder C (1985) Disappearance and reappearance of islet cell cytoplasmatic antibodies in cyclosporin-treated insulin-dependent diabetics. Lancet 2: 599-602
17. 17. Mandrup-Poulson T, Molvig J, Andersen HU, Helqvist S, Spinas GA, Munck M, the Canadian-European Randomized Control Trial Group (1990) Lack of predictive value of islet cell antibodies, insulin antibodies and HLA-DR phenotype for remission in cyclosporin-treated IDDM patients. Diabetes 39: 204-210
18. 18. Castano L, Boitard C, Bougneres PF (1988) Cyclosporine A suppresses insulin autoantibodies and heterologous insulin antibodies in type I diabetic children. Diabetes 37: 1049-1052
19. 19. Erlanger BE (1992) Do we know the site of action of cyclosporine? Immunol Today 13: 487-491
20. 20. Kang SO, Tsang W, Doll S, Scherle P, Ko HS, Tran AC, Lenardo MJ, Straudt LM (1992) Induction of the POU domain transcription factor Oct-2 during T-cell activation by kognate antigen. Mol Cell Biol 12: 3149-3154